Kumiko Torisu

Kumiko Torisu

Auto-generated profile, based on publicly available information

Kumiko Torisu

Department of Integrated Therapy for Chronic Kidney Disease, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2023 in Communications Biology
Verified
Journal Article
Open access
PDF file
SASeishi Aihara
Seishi Aihara
KTKumiko Torisu
Kumiko Torisu
YUYushi Uchida
Yushi Uchida
NINoriyuki Imazu
Noriyuki Imazu
TNToshiaki Nakano
Toshiaki Nakano
TKTakanari Kitazono
Takanari Kitazono
Kidney metabolism may be greatly altered in chronic kidney disease. Here we report that arginine metabolism is the most altered in unilateral ureteral obstruction (UUO)-induced fibrosis of the kidneys in metabolomic analysis. Spermidine is the most increased metabolite of arginine. In human glomerulonephritis, the amount of spermidine shown by immunostaining is associated with the amount of fibrosis. In human proximal tubule cells, spermidine induces nuclear factor erythroid 2-related factor 2 (Nrf2). Subsequently, fibrotic signals, such as transforming growth factor β1 secretion, collagen 1 mRNA, and oxidative stress, represented by a decrease in the mitochondrial membrane potential is suppressed by spermidine. UUO kidneys of Arg2 knockout mice show less spermidine and significantly exacerbated fibrosis compared with wild-type mice. Nrf2 activation is reduced in Arg2 knockout UUO kidneys. Spermidine treatment prevents significant fibrotic progression in Arg2 knockout mice. Spermidine is increased in kidney fibrosis, but further increases in spermidine may reduce fibrosis.

11 December 2017 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
RYRyusuke Yotsueda
Ryusuke Yotsueda
STShigeru Tanaka
Shigeru Tanaka
MTMasatomo Taniguchi
Masatomo Taniguchi
KFKiichiro Fujisaki
Kiichiro Fujisaki
KTKumiko Torisu
Kumiko Torisu
Kazuhiko TsuruyaKazuhiko Tsuruya
Kazuhiko Tsuruya
The contribution of the hemoglobin concentration to the incidence of hemorrhagic or ischemic stroke in patients undergoing hemodialysis is unclear. In total, 3436 patients undergoing prevalent hemodialysis were followed up for 4 years. The primary outcome was the first development of hemorrhagic or ischemic stroke. The baseline hemoglobin concentration was divided into quartiles [hemoglobin (g/dL): Q1, ≤9.7; Q2, 9.8–10.5; Q3, 10.6–11.1; Q4, ≥11.2]. The association between the hemoglobin concentration and each type of stroke was examined using the Kaplan–Meier method and a Cox proportional hazards model. During the follow-up period, 76 (2.2%) patients developed hemorrhagic stroke and 139 (4.0%) developed ischemic stroke. The 4-year incidence rate of hemorrhagic stroke was significantly higher in patients with lower hemoglobin concentrations. Compared with the quartile of patients with the highest hemoglobin concentrations (Q4), the multivariable-adjusted hazard ratios for hemorrhagic stroke were 1.18 (95% confidence interval, 0.56–2.51), 1.59 (0.82–3.21) and 2.31 (1.16–4.73) in patients in Q3, Q2 and Q1, respectively. No association was identified between the 4-year incidence rate of ischemic stroke and the hemoglobin concentration. Compared with the quartile of patients with the lowest hemoglobin concentrations (Q1), the multivariable-adjusted hazard ratios for ischemic stroke were 1.17 (95% confidence interval, 0.73–1.89), 0.88 (0.51–1.51) and 1.10 (0.66–1.83) in patients in Q2, Q3 and Q4, respectively. Our results suggest that low hemoglobin concentrations are associated with a high risk of hemorrhagic stroke, but not of ischemic stroke, in patients undergoing hemodialysis.

3 August 2023 in Laboratory Investigation
Verified
Journal Article
Closed access
YUYushi Uchida
Yushi Uchida
KTKumiko Torisu
Kumiko Torisu
SASeishi Aihara
Seishi Aihara
NINoriyuki Imazu
Noriyuki Imazu
HOHiroaki Ooboshi
Hiroaki Ooboshi
TNToshiaki Nakano
Toshiaki Nakano

9 May 2023 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SASeishi Aihara
Seishi Aihara
KTKumiko Torisu
Kumiko Torisu
YHYutaro Hirashima
Yutaro Hirashima
TKTakanari Kitazono
Takanari Kitazono
TNToshiaki Nakano
Toshiaki Nakano

1 November 2021 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Closed access
PDF file
YUYushi Uchida
Yushi Uchida
KTKumiko Torisu
Kumiko Torisu
KUKenji Ueki
Kenji Ueki
KTKazuhiko Tsuruya
Kazuhiko Tsuruya
TNToshiaki Nakano
Toshiaki Nakano
TKTakanari Kitazono
Takanari Kitazono
Receptor-mediated albumin transport in proximal tubule epithelial cells (PTECs) is important to control proteinuria. Autophagy is an evolutionarily conserved degradation pathway, and its role in intracellular trafficking through interactions with the endocytic pathway has recently been highlighted. Here, we determined whether autophagy regulates albumin transcytosis in PTECs and suppresses albumin-induced cytotoxicity using human proximal tubule (HK-2) cells. The neonatal Fc receptor (FcRn), a receptor for albumin transcytosis, is partially colocalized with autophagosomes. Recycling of FcRn was attenuated, and FcRn accumulated in autophagy-related 7 (ATG7) knockdown HK-2 cells. Colocalization of FcRn with RAB7-positive late endosomes and RAB11-positive recycling endosomes was reduced in ATG7 knockdown cells, which decreased recycling of FcRn to the plasma membrane. In ATG7 or autophagy-related 5 (ATG5) knockdown cells and Atg5 or Atg7 knockout mouse embryonic fibroblasts, albumin transcytosis was significantly reduced and intracellular albumin accumulation was increased. Finally, the release of kidney injury molecule-1, a marker of tubule injury, from ATG7 or ATG5 knockdown cells was increased in response to excess albumin. In conclusion, suppression of autophagy in tubules impairs FcRn transport, thereby inhibiting albumin transcytosis. The resulting accumulation of albumin induces cytotoxicity in tubules. NEW & NOTEWORTHY Albumin transport in proximal tubule epithelial cells (PTECs) is important to control proteinuria. The neonatal Fc receptor (FcRn), a receptor for albumin transcytosis, is partially colocalized with autophagosomes. Recycling of FcRn to the plasma membrane was decreased in autophagy-related 7 (ATG7) knockdown cells. In addition, albumin transcytosis was decreased in ATG7 or autophagy-related 5 (ATG5) knockdown PTECs. Finally, release of kidney injury molecule-1 from ATG7 or ATG5 knockdown cells was increased in response to excess albumin.

12 September 2021 in CEN Case Reports
Verified
Journal Article
Open access
PDF file
KUKenji Ueki
Kenji Ueki
ATAkihiro Tsuchimoto
Akihiro Tsuchimoto
KTKumiko Torisu
Kumiko Torisu
KFKiichiro Fujisaki
Kiichiro Fujisaki
STSayaka Tachibana
Sayaka Tachibana
TKTakanari Kitazono
Takanari Kitazono
Dialysate leakage is one of the causes of peritoneal dialysis (PD)-related peritonitis. The rate of catheter removal in PD-related peritonitis caused by dialysate leakage (PDPDL) is high, and the correct treatment is unclear. We experienced a case of PDPDL that was treated with intravenous and intraperitoneal antibiotic therapy. A 44-year-old Japanese man had high glucose discharge from the exit site after 14 days of initiating PD, and he had a fever and cloudy effluent with a high white cell count. We diagnosed him with PDPDL and began to administer vancomycin and ceftazidime intraperitoneally. However, the peritonitis could not be ameliorated. A culture examination showed Staphylococcus aureus from the effluent of peritoneal cavity and exit site cultures. We began intraperitoneal cefazolin administration according to a drug susceptibility test, but the effluent cell count remained high. As we added intravenous cefazolin administration, his symptoms and cloudy effluent improved, and the effluent cell count normalized. He has not developed any recurrence of dialysate leakage or peritonitis. Our findings suggest that PD-related peritonitis accompanied by other infectious sites, such as PDPDL, should be treated with additional intravenous antibiotic therapy to taking effect on the infectious sites except for peritoneum and to keep plasma concentration of antibiotics sufficient especially in cases with preserved residual kidney function.